GlassScriptPhysician profile
Robert M Crescentini
NPI 1609079797
$1,162.55
in general payments reported to CMS, 2019-2025
24 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $159 · 2021: $187 · 2022: $137 · 2023: $154 · 2024: $64.28 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $349 · Education: $18.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.80 |
| Education | $18.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $144.42 | 2019-2024 | |
| Eisai INC. | $138.10 | 2020-2024 | |
| Lilly USA, LLC | $116.12 | 2019 | |
| Sobi, INC | $99.13 | 2020 | |
| Pfizer INC. | $82.54 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $66.55 | 2020-2025 | Xpovio |
| Genentech USA, INC. | $64.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $51.98 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.51 | 2022-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $44.24 | 2020-2021 | |
| Exelixis INC. | $35.20 | 2023-2025 | Cabometyx |
| Sirtex Medical INC | $29.16 | 2022 | |
| Emmaus Medical, INC. | $27.98 | 2023 | Endari |
| Taiho Oncology, INC. | $26.67 | 2025 | |
| Fennec Pharmaceuticals, INC. | $24.58 | 2025 | Fyarro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $23.93 | 2021 | |
| Pharmacosmos Therapeutics INC. | $22.48 | 2021 | |
| Astellas Pharma US INC | $21.85 | 2024 | Xtandi |
| Genzyme Corporation | $21.56 | 2023 | |
| Seagen INC. | $19.37 | 2022 | |
| Ge Healthcare | $19.18 | 2022 | |
| Janssen Biotech, INC. | $16.46 | 2021 | |
| Penumbra, INC. | $14.75 | 2023 | Indigo System |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Crescentini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.